Fredun Pharmaceuticals Delivers Strong H1 FY27 Growth with Strategic Pet-Care Expansion
Fredun Pharmaceuticals Ltd · Press Release · 06 Nov 2026, 2:32 pm
Fredun Pharmaceuticals Delivers Strong H1 FY27 Growth with Strategic Pet-Care Expansion Fredun Pharmaceuticals reported robust standalone financial results for H1 FY27, with total income rising 87.02% YoY to ₹495.88 Cr. EBITDA surged 91.67% YoY to ₹75.38 Cr as EBITDA margins expanded 37 bps to 15.20%, while net profit rose 93.92% YoY to ₹31.99 Cr. For Q2 FY27, total income grew 84.21% YoY to ₹267.64 Cr and net profit rose 93.44% YoY to ₹18.83 Cr. Strategically, Fredun expanded its pet-wellness ecosystem in Sep'26 by acquiring Furlicks and securing a 26% stake in Goodman Vetcare at a ₹300 Cr valuation.
Original exchange filing (PDF)
More announcements from Fredun Pharmaceuticals Ltd
- Audio Recording Q2 & H1 FY27 Earnings Conference Call of Fredun Pharmaceuticals Limited. · 16 Nov 2026
- Outcome of the Board Meeting of 'Fredun Pharmaceuticals Limited' ('Company') pursuant to Regulation 30 of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. · 14 Nov 2026
- Report of Monitoring Agency on the use of proceeds raised through Preferential Allotment for the quarters ended March 31, 2026, June 30,2026 and September30, 2026. · 14 Nov 2026
- Statement of Deviation or Variation For the Quarter Ended September 30, 2026 for the Funds raised through Preferential Issue. · 14 Nov 2026
- Intimation of Earnings Conference Call for the Quarter Q2 of FY27 · 16 Nov 2026
- Approval for National Stock Exchange of India Limited (NSE) Listing Application. · 05 Nov 2026
- Financial results for the quarter ended 30th September, 2026. · 05 Nov 2026
- Outcome of the Board Meeting dated 05th November, 2026. · 05 Nov 2026
